

CONTACT: Brian Bennett  
(501) 225-9733



*(For Immediate Release)*

**i3 DRUG SAFETY TO PROVIDE GLOBAL MEDICAL  
COMMUNITY ACCESS TO INFORMATION ON H1N1 VACCINE  
SAFETY**

*Surveillance Program Will Provide Near Real-Time Information to Help Identify  
Safety Issues Quickly*

**ANN ARBOR, MI November 4, 2009**—Pharmaceutical services company i3 announced today that i3 Drug Safety, a leading provider of pharmacovigilance and epidemiology services to the biopharmaceutical industry, has established an H1N1 vaccine safety surveillance program to provide access to immediate and comprehensive information about H1N1 vaccine safety to members of the global medical community including governments, public health agencies, and other healthcare entities.

i3 Drug Safety’s surveillance program was launched in response to the widespread demand for rapid availability of post-vaccine monitoring information, as manufacturers attempt to meet the increasing demand for the vaccine around the world.

With an Institutional Review Board (IRB) - approved research study under way, i3 Drug Safety is able to capture medical claims information relating to the H1N1 vaccine and health outcomes in near real time, enabling its epidemiologists and other experts to identify and assess targeted safety issues. Using the information resources of its parent company, Ingenix, i3 Drug Safety will efficiently assemble relevant information about H1N1 vaccine performance for reporting to the medical community as quickly as possible.

“Through this program, we have an unparalleled capability to access near real-time information to monitor the health care experience of patients who receive the H1N1 vaccine,” said Glenn Bilawsky, chief executive officer of i3. “We are pleased to help authorities use our uniquely comprehensive information resources to provide aggregated results quickly, and empower health care providers and others to make smarter decisions in the interest of public health.”

-more-

## **H1N1 SURVEILLANCE/2**

### **About i3**

i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It is composed of i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, engaged in pharmacovigilance and epidemiology; i3 Pharma Informatics, a data, science and technology provider of market analytics; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; and i3 Innovus, delivering the science and solutions to achieve marketplace success. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit [www.i3global.com](http://www.i3global.com).

# # #